CARsgen Therapeutics Holdings Limited and Huadong Medicine (Hangzhou) Co. Ltd., a wholly-owned subsidiary of Huadong Medicine Co. Ltd. announced a collaboration for the commercialization of CARsgen's BCMA CAR-T product CT053 in mainland China.

CT053, zevorcabtagene autoleucel ("zevor-cel"), is CARsgen's lead drug candidate and an autologous CAR T-cell product treating relapsed/refractory multiple myeloma (R/R MM). CT053 NDA was submitted to NMPA in October 2022. With strong commercial capability and network, Huadong Medicine is granted the exclusive right to commercialize zevor-cel in mainland China.

Under the terms of the agreement, CARsgen will receive an upfront payment of RMB200 million and is eligible to receive regulatory and commercial milestone payments up to RMB1,025 million. CARsgen will continue to be responsible for the development, regulatory approval, and manufacturing of CT053 in mainland China.